Skip to content

Financial Reports and Presentations

Report Presentation Webcast Poster
February 29, 2024 Year-end report for 2023
February 29, 2024 Annual Review 2023
February 29, 2024 Financial Statements 2023 (Finnish)
January 26, 2024 Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
January 9, 2024 Nanoform Management Presentation - SEB Nordic Seminar Copenhagen
December 14, 2023 DNB Nordic Healthcare Conference
November 29, 2023 Carnegie Finnish Healthcare Seminar
November 23, 2023 SEB Annual Healthcare Seminar
November 22, 2023 Interim Report for January-September 2023
August 24, 2023 Interim Report for January-June 2023
July 4, 2023 Nanoforming - the Patient- and Planet-Centric Approach From Increasing Bioavailability to Enabling Sustained Drug Delivery
May 25, 2023 Interim Report for January-March 2023
February 28, 2023 Year-end report for 2022
February 28, 2023 Annual Review 2022
February 28, 2023 Financial Statements 2022 (Finnish)
January 9, 2023 SEB Nordic Seminar in Copenhagen
November 29, 2022 Interim Report for January-September 2022
October 25, 2022 Nanoform and TargTex – How drug delivery is enabling a clinical trial for Glioblastoma
August 25, 2022 Interim Report for January-June 2022
May 24, 2022 Interim Report for January-March 2022
February 22, 2022 Year-end report for 2021
February 22, 2022 Financial Statements 2021 (Finnish)
February 22, 2022 Annual Review 2021
November 25, 2021 Interim Report for January-September 2021
August 26, 2021 Interim Report for January-June 2021
June 4, 2021 Capital Markets Day 2021
May 27, 2021 Interim Report for January-March 2021
February 26, 2021 Annual Review 2020
February 26, 2021 Year-end report for 2020
February 26, 2021 Financial Statements 2020 (Finnish)
November 27, 2020 Interim Report for January-September 2020
August 28, 2020 Half-year Financial Report for January-June 2020
March 17, 2020 Financial Statements 2019 (Approved by AGM 2020) - English
March 17, 2020 Vuosikertomus 2019 (Yhtiökokouksen 2020 hyväksymä)

Questions from investors, analysts and journalists